Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Biomarker evaluation after autologous BM-MSC therapy in ALS
IRCT20160809029275N5Phase 3Completed
- Sponsor
- Mashhad University of Medical Sciences
- Start
- Dec 2022
- Modality
- Stem Cell Therapies → Cell Therapies
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of autologous bone marrow derived mesenchymal stromal cells in amyotrophic lateral sclerosis (ALS), sponsored by Mashhad University of Medical Sciences. Primary endpoints: ALS Functional Rating Scale-Revised score, Forced vital capacity and 7 more. Started Dec 2022; status: completed.
02
Drugs
autologous bone marrow derived mesenchymal stromal cells
03
Conditions
amyotrophic lateral sclerosis (ALS)
Beyond the preview
Go deeper on IRCT20160809029275N5.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20160809029275N5.